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Abstract
Attention deficit hyperactivity disorder (ADHD) is a lifelong condition associated with considerable costs. The long-term
effectiveness and acceptability of treatments to improve outcomes remains in doubt. Long-term trials are needed comparing
interventions with standard care and each other. The Sheffield Treatments for ADHD Research (STAR) project used the Trials
within Cohorts (TwiCs) approach. A cohort of children with ADHD was recruited and outcomes collected from carers and
teachers. A random selection was offered treatment by homoeopaths (hom) or nutritional therapists (NT). Their outcomes
(Conners Global ADHD Index) were compared with those not offered interventions. The feasibility of the methods and inter-
ventions was assessed. The TwiCs approach was feasible with modifications. 144 participants were recruited to the cohort, 83
offered treatment, 72 accepted, and 50 attended 1+ appointments. Results according to carers assessments at 6 months were as
follows: t = 1.08, p = .28 (− 1.48, 4.81) SMD .425 (hom); t = 1.71, p = .09 (− .347, 5.89), SMD= .388 (NT). Teachers’ responses
were too few and unstable. No serious treatment adverse events occurred.
Conclusion: the STAR project demonstrated the feasibility of the TwiCs approach for testing interventions for children with
ADHD.
What is Known:
• Attention deficit hyperactivity disorder (ADHD) is a lifelong condition associated with considerable costs to ADHD stakeholders. Children are at risk
of negative outcomes and in need of pre-emptive strategies
• The long-term effectiveness and acceptability of recommended treatments to improve outcomes remains in doubt
What is New:
• A small-scale test of the design demonstrated that the Trials within Cohorts (TwiCs) approach is feasible and can make a useful contribution regarding
testing the effectiveness of interventions for children with ADHD to improve long-term negative outcomes
• Treatment by homoeopaths and nutritional therapists may offer novel opportunities to improve outcomes.
Keywords Attention deficit hyperactivity disorder . Homoeopathy . Nutritional therapy . Trials within cohorts
Abbreviations
ADHD Attention deficit hyperactivity disorder
CGI Conners Global ADHD Index
CHU 9D Child Health Utility–9 Dimensions
CTCAE Common Terminology Criteria
for Adverse Events
Hom Treatment by homoeopaths
HRQOL Health-related quality of Life
ITT Intention to treat
NT Treatment by nutritional therapists
RCT Randomised controlled trial
SPSS Statistical Package for the Social Sciences
SMD Standardised mean difference
STAR Sheffield Treatments for ADHD Research
TwiCs Trials within Cohorts
Communicated by Mario Bianchetti
* Philippa Fibert
p.fibert@sheffield.ac.uk
Tessa Peasgood
t.peasgood@sheffield.ac.uk
Clare Relton
c.relton@sheffield.ac.uk; c.relton@qmul.ac.uk
1 School of Health and Related Research, University of Sheffield,
Regent Coutrt, 30 Regent Street, Sheffield S1 4DA, UK
2 Health Economics and Decision Science,West Court, Mappin Street,
Sheffield, S1 4DP, UK
3 Pragmatic Clinical Trials Unit, Centre for Primary Care and Public
Health, Queen Mary’s University, 58 Turner Street, London, UK
European Journal of Pediatrics
https://doi.org/10.1007/s00431-019-03374-z
Introduction
Attention deficit hyperactivity disorder (ADHD) is a lifelong
condition associated with considerable costs to a significant
proportion of those with ADHD, their carers, and society. It is
a leading cause of child referrals to mental health services, and
a major risk factor for early criminality, poor educational out-
comes, school drop-out, and expulsion.
Although short-term effects (12 weeks) are reported for
pharmaceutical medications, and behavioural interventions
during participation, the long-term effectiveness and accept-
ability of mainstream recommended treatments to improve
outcomes remains in doubt [5, 29–31]. Medications are not
well tolerated and associated with side effects such as reduced
growth over the long term [30]; nausea, reduced appetite,
sleep problems in the short term [21]; and long-term effects
are not established in the few trials conducted. The effects
found during participation in behavioural interventions are
contested due to lack of blinded outcomes, and lack of im-
provement in core ADHD symptoms [35]. Other interventions
are tried by carers [3, 10–12], but their effectiveness has not
yet been rigorously assessed.
If outcomes for those with ADHD, their carers, and society
are to improve, there is a need to rigorously evaluate the long-
term effectiveness and acceptability of interventions by
conducting long-term trials comparing promising interven-
tions with standard care and with each other. The standard
approach is to conduct short, stand-alone trials comparing an
intervention with a placebo or another intervention. Trialling
interventions of different types, one at a time by different
research teams, using different designs, comparators, inclu-
sion criteria and measurements, is financially and scientifical-
ly inefficient. It makes interventions difficult to compare, and
may not inform whether they improve long-term outcomes.
In order to rigorously and comparatively assess the
effectiveness and acceptability of interventions which
might improve outcomes for those with ADHD, their
carers, and society, we piloted a novel, alternative ap-
proach to randomised controlled trial (RCT) design—the
Trials within Cohorts (TwiCs) approach. The TwiCs de-
sign was developed to address shortcomings associated
with conducting RCTs, such as recruitment, ethics, patient
preferences, and treatment comparisons, and more closely
replicate real-world routine health care [23]. It is being
applied globally in at-risk cohorts of children particularly
where the aim is to improve long-term outcomes (https://
www.twics.global/use-of-the-design).
The TwiCs approach entails recruitment of a large ob-
servational cohort and regular measurement of their out-
comes. For each RCT, eligible participants are identified
from the cohort and some randomly selected to be offered
the trial intervention(s). Their outcomes are compared
with those of eligible participants not selected (that is,
receiving usual care). The approach enables reliable com-
parisons because all treatments have the same parameters
and risk of bias, are conducted within the same popula-
tion, and measure the same outcomes. Currently, the two
main treatment categories for ADHD (behavioural and
pharmaceutical) are difficult to compare because they dif-
fer in these aspects.
The Sheffield Treatments for ADHD Research (STAR)
Project was set up with the aim of improving outcomes for
those wi th ADHD (h t tps : / /www. facebook .com/
starsheffieldADHD, www.starsheffield.com). This article
reports the results of Stage 1 of the STAR project, which
was to assess the feasibility of the TwiCs trial design to
provide suitable information for stakeholders to enable
evaluation of the clinical and cost effectiveness of some
treatments for ADHD identified as being used by carers.
This was done by conducting a small-scale test of the
methods and procedures: a three-armed internal pilot trial
of the clinical and cost effectiveness of (a) the offer of ad-
junctive treatment by homoeopaths and (b) the offer of ad-
junctive treatment by nutritional therapists, compared with
(c) treatment as usual [7] (ISRCTN17723526).
The objectives were to assess the feasibility of
recruiting a cohort of children with a diagnosis of
ADHD to time and target; test the feasibility and accept-
ability of the study design; the feasibility, deliverability,
safety, acceptability, preliminary clinical, and cost effec-
tiveness of the interventions; the suitability, acceptability,
and deliverability of the outcome measures; and inform
the sample size calculation for the full trial. Key feasibil-
ity criteria and parameters are summarised in Table 1.
Reporting follows Consort guidelines, using the extension
for the reporting of pragmatic trials [34].
Methods
Recruitment of the STAR cohort
Figure 1 describes the study progression. Children with
ADHDwere recruited to an observational cohort from a broad
variety of sources. Cohort inclusion criteria were children
aged 5–18 (inclusive) with a carer-reported diagnosis of
ADHD and Conners’ Global ADHD Index (CGI) T score of
at least 55 [4], and any co-morbidities. Exclusion criteria were
children with terminal or life-threatening conditions, and fam-
ilies where English was not written or spoken.
Collection of outcomes
Outcomes were collected from carers and children’s schools at
0, 6, and 12 months via questionnaires. Carers could opt to
provide details of their child’s school and if they did, school
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questionnaires were sent to the head teachers asking someone
who knew the child well to complete the questionnaire. Carers
were reminded to return the questionnaires via 3 monthly
emails and test messages. Teacher outcomes were requested
just once by post.
The primary outcome measure was the ten item CGI with
sub-scores restlessness/impulsivity (7 items) and emotional
lability (3 items) [23] at 6 months. Carers also completed a
child health–related quality of life measure (CHU 9D) [26].
The pilot RCT
For the first trials embedded in the STAR cohort, a proportion
of eligible participants were randomly selected and offered
treatment by homoeopaths or by nutritional therapists.
Inclusion criteria for the pilot trial were a carer-reported
ADHD diagnosis and CGI T score of 65+. Exclusion criteria
were children currently receiving treatment by a homoeopath
or a nutritional therapist.
Table 1 Feasibility criterion and results
Criteria (section) Measurement: criteria
parameters
Results Continuation to a full trial
yes/no/recommendations
Recruitment to cohort rates # recruited in 2 years: %
recruited /sample size estima-
tion
144 recruited in 1 year Yes
Recruitment to treatment rates % of eligible participants
recruiting to the cohort
accepting an offer: At least
30%
23/41 (56%) hom; 27/42 (64%)
NT
Yes
Treatment effects (SMD baseline-6 months) SMD CGI: mean = < .3 in those
implementing a therapy
36 hom; .55 NT Yes
Treatment effects (clinical significance) CGI T score: 5 percentiles Use of T scores not feasible
due to ceiling effects.
SMD (above) used instead
Attrition. Cohort # CQ’s returned at 6 months: at
least 30%
70% (88/124) 6-month ques-
tionnaires returned
Yes
Attrition. Consultations # consultations attended: 70% of
participants accepting
intervention attend at least 3
consultations
39/42 NT; 33/41 homaccepted
the offer.
No
18/39 (46%) NT; 17/33 (52%)
hom had 3+ consults.
Acceptability of TQ #TQs completed at baseline and
6 months: # of reminders
needed; #
email/telephone/paper
responses. Adjustment of
measure, collection method,
and trial parameters
54 (43.5%) completed at
baseline. 46 (37.1%)
completed at 6 months.
Current methods not feasible:
more reminders by a
variety of methods needed
Acceptability of CQ # reminders needed: adjustment
of measure, collection
method, and trial parameters
Maximum reminders: 3 emails,
1 text, 1 letter.
£10 Boots vouchers
introduced improved
return rate
Adverse events Clinician records: no
intervention-related severe
adverse events, as defined by
CTCAE (2010) and EC
(2011) guidelines.
No severe events Yes
Appropriate outcome measurement–CQ # missing items: adjustment of
measure.
5 items missing from paper
questionnaires
Continue using on-line ques-
tionnaires
Recruitment of therapists # recruited fulfilling criteria: at
least 2 for each therapy
8 therapists (hom); 4 therapists
(NT)
One (hom) dropped out/-
unsuitable. Two (hom)
using a receptionist and
one (NT) only using email
made poor contact with
participants.
Suitability of consultation venues/mode ANCOVA (venue/mode as
variable): No venue/mode to
have statistically significant
impact on treatment effect
This could not be calculated as
some therapists used several
modes.
Statistical analysis ANCOVA: meets assumptions Outliers not improved with
transformation
Regression analysis used.
Assumptions met.
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Randomisation was performed by an independent statisti-
cian at the University of Sheffield in blocks of 6 with stratify-
ing factors age, medication status, and ADHD severity. The
randomisation list was housed in the locked drawer of another
independent statistician who randomly assigned participants
to one of the three groups.
Those randomised to usual care were not informed that
they had not been selected for a treatment. Those selected to
be offered treatment were sent a letter offering them 1 year of
that treatment, a brief description of what to expect, and ask-
ing carers to confirm their child was happy to participate. If
both consented, their designated therapist arranged appoint-
ments with them. If therapists failed three times to make con-
tact with participants, they were deemed non-responders.
Eight therapists (4 nutritional therapists and 4
homoeopaths) were initially recruited via Wellforce
Integrated Medicine Centre in Sheffield, UK. Consultations
mirrored usual practice: they took place in therapist’s usual
treatment venues; were delivered according to usual modes
(face to face, telephone, or on-line); missed appointments
were rebooked; and times between consultations and number
of consultations varied. Before the trial, therapists attended
Apply to the STAR cohort
(n= 144)
Recruited to the 1st RCT and randomised
(n=125)
Oﬀered treatment by a nutrional
therapist (n=42)
Accept oﬀer (n=39)
Aend at least one appointment (n=27)
Teacher baseline outcomes (n=23)
Complete 6-month outcomes
n=28 carers
n=8 teachers
Allocated treatment as usual (n=41)
Teacher baseline outcomes (n= 28)
Complete 6-month outcomes
n=31 carers
n=12 teachers
Oﬀered treatment by a homeopath (n=42)
Protocol violaon (n=1)
Accept oﬀer (n=33)
Aend at least one appointment (n=23)
Teacher baseline outcomes (n= 23)
Complete 6-month outcomes
n=29 carers
n=14 teachers
Excluded from the STAR cohort (n=19)
- Not meeng inclusion criteria (n=10)
- Declined to be contacted again (n=5)
- No contact details provided (n=4)
Complete 12-month outcomes
n=19 carers
n=8 teachers
Complete 12-month outcomes
n=17 carers
n=14 teachers
Complete 12-month outcomes
n=22 carers
n=6 teachers
Fig. 1 Study progression
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workshops in management of ADHD, and identification and
management of abuse and safeguarding of children.
Participants’ doctors were sent letters explaining that their
patients were participating in a trial, describing the ethical
approvals and safeguards in place, confirming that interven-
tions should not interfere with pharmaceutical medication, and
that participants were advised to continue with their current
treatments. Adverse events were recorded according to the
Common Terminology Criteria for Adverse Events [32]
guidelines and European Commission guidelines [6] and in-
dependently assessed by two researchers.
Statistical analysis
IBM SPSS 21 statistical software was used. Tests were two-
tailed with significance level (alpha) set to 5%, and 95% con-
fidence intervals were presented. Each treatment was com-
pared with usual care. Change scores were calculated by
subtracting 6-month scores from baseline scores (lower scores
indicate better outcomes).
Preference weights were added to health-related quality of
life measure CHU 9D, derived from the application of the
standard gamble method from 300 members of the UK adult
population [27]. This estimates the importance of change in
one item versus change in another and versus extending years
of life, and gives a score where 0 is equivalent to being dead
and 1 represents full health.
The primary outcome used intention to treat (ITT) analysis,
whereby all participants offered treatment remained within the
treatment group regardless of whether or not they took up the
offer of treatment. Secondary analyses explored the effect of
having a treatment on the outcome to inform feasibility criterion.
Statistical testing was exploratory since the pilot study was
not powered to detect statistical differences. Regression anal-
ysis explored the predictive power of the offer of treatment,
with analyses controlling for the effects of gender, ADHD
severity, and age. Standardised mean differences (SMDs)
(Cohen’s d) explored the magnitude of the clinical effect and
provided estimates for the sample size required in the full trial.
Results
Recruitment and participation in the STAR cohort
A total of 144 participants completed the carer questionnaire
between September 2015 and 2016. 19/144 (13%) did not
meet the cohort inclusion criteria or could not be included
(no contact details or declining to be contacted again).
A total of 125 cohort participants were eligible for the trial
and randomised: 42 to treatment by homoeopaths (hom), 42 to
treatment by nutritional therapists (NT), and 41 to remain in
the usual care group (TAU). One child randomised to
treatment by a homoeopath was found to be very sick and
awaiting a liver transplant when telephoned to be allocated a
therapist. Since this was in violation of the protocol, he was
withdrawn from the trial. Seventy-two of the 83 participants
offered a treatment accepted it. 50/72 (n = 23 hom; n = 27 NT)
took up their offer and had at least one consultation. Figure 2
describes reasons for non-participation.
Questionnaire return
A total of 124 baseline Carer Questionnaires, 88 6-month
questionnaires, and 58 12-month questionnaires were
returned. Of those randomised to a treatment, the majority
of returned 6-month (20/29 hom; 24/28 NT) and 12-month
(16/22 hom; 16/19 NT) questionnaires were from those who
had that treatment. There were just five instances of missing
data in the few paper Carer Questionnaires. Last observa-
tion carried forward was used to impute the missing data in
these few instances.
Teacher outcomes were potentially available from a maxi-
mum of 100 teachers, since 20 carers refused permission for
their child’s school to be contacted and 4 children were home
schooled. Seventy-two baseline, 34 6-month, and 58 12-
month Teacher Questionnaires were returned. Schools did
not return questionnaires consistently: 31 paired baseline and
6-month questionnaires, 14 paired 6 and 12-month question-
naires, and 21 paired baseline and 12-month questionnaires
were returned. Thirty-five percent of paired questionnaires
were returned by different teachers.
The pilot RCT
Randomised groups were similar regarding age and medica-
tion status. Fewer with an autism diagnosis were offered NT.
Those participants who received a treatment were less likely
(but non-significantly so according to log-linear analysis) to
have autism or be on ADHD medication, and to have more
severe ADHD (Table 2).
Data analysis of carer ratings
Primary outcome (ITTanalysis of CGI total score at 6 months)
results are presented in Table 3 together with per protocol
results. Data met assumptions for conducting parametric anal-
yses. When CGI total change score was the dependent vari-
able and group (hom or NT), age, gender, and ADHD severity
the covariates, the model explained a significant amount of the
variance in CGI change score due to the highly significant
influence of ADHD severity (t = 4.225, p < .001). Neither
treatment group, age, nor gender explained a significant
amount of variance. Standardised mean differences (SMDs)
were as follows: hom .425; and NT .388.
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The variance in both CGI subscale change scores was ex-
plained by the influence of ADHD severity, and treatment by a
homoeopath also explained a significant amount of the vari-
ance in the emotional dysregulation change score (t = 2.09,
p = .04). SMD = .793 and treatment by nutritional therapists
neared statistical significance for the restlessness/impulsivity
change score (t = 1.8, p = .075). SMD = .418.
Although improvements sustained at 6 months in treat-
ment groups remained stable at 12 months, some partici-
pants in the usual care group registered large improve-
ments at 12 months (Table 2).
Teacher ratings
Testing may not be valid given the very small number of
paired questionnaire returns, compounded by additional un-
certainty since 1/3 were completed by different teachers. At
6 months, the positive direction of improvements in NT ac-
cording to ITT analysis (SMD= .39) became a negative direc-
tion when only those accessing treatment were considered
(SMD= − .504). None of the covariates entered into the mod-
el explained a significant amount of the variance in teacher-
rated CGI total or sub-scores (Table 3).
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Table 2 Demographic and clinical characteristics of study participants according to those offered interventions, those receiving interventions; and
those continuing with usual care, at baseline, 6, and 12 months
Hom offered Hom received NT offered NT received TAU All
Sample size (i.e. questionnaire return)
Baseline N = 41 N = 23 N = 42 N = 27 N = 41 N = 124
6 months N = 29 N = 20 N = 28 N = 23 N = 31 N = 88
12 months N = 22 N = 16 N = 19 N = 16 N = 17 N = 58
Mean (standard deviation)
Age 10.17 (2.42) 9.78 (2.22) 10.05 (2.46) 10.22 (2.68) 10.41 (2.49) 10.21 (2.44)
Female 8 (19.5%) 5 (21.7%) 7 (16.6%) 4 (14.8%) 5 (12.2%) 20 (16.1%)
Taking pharmaceutical medication 28 (68%) 13 (56.5%) 29 (69%) 20 (74%) 27 (65.9%) 84 (67.7%)
Have autism 13 (10%) 6 (5%) 9 (7%) 6 (5%) 15 (12%) 37 (30%
CGI baseline 23.9 (3.56) 23.48 (3.27) 23.9 (3.56) 23.4 (3.87) 22.27 (4.62) 23.1 (4.17)
CGI 6 months 20.0 (6.15) 19.65 (5.83) 18.82 (5.59) 18.48 (5.27) 20.06 (5.29) 19.65 (5.64)
CGI 12 months 19.91 (6.05) 19.63 (5.8) 19.84 (5.5) 19.63 (5.6) 17.88 (6.7) 19.27 (6.03)
Restless/impulsive baseline 17.61 (2.63) 17.3 (2.55) 17.4 (3.09) 17.67 (3) 16.98 (3.41) 17.33 (3.05)
Restless/impulsive 6 months 15.28 (4.6) 14.9 (4.35) 13.68 (3.89) 13.39 (3.6) 15.19 (3.73) 14.74 (4.1)
Restless/impulsive 12 months 15.18 (4.14) 14.88 (3.56) 14.42 (4.14) 14.25 (4.37) 13.71 (5.24) 14.5 (4.44)
Emotional lability baseline 6.39 (1.56) 6.17 (1.59) 5.67 (2.09) 5.74 (1.99) 5.29 (1.93) 5.29 (1.92)
Emotional lability 6 months 4.72 (2.15) 4.75 (2.14) 5.14 (2.1) 5.09 (2.09) 4.87 (2.28) 4.91 (2.16)
Emotional lability 12 months 4.73 (2.43) 4.75 (2.59) 5.42 (2.19) 5.38 (2.13) 4.18 (2.67) 4.79 (2.44)
CHU9D utility scores baseline .679 (.114) .676 (.122) .696 (.106) .695 (.121) .708 (.104) .694 (.108)
CHU9D utility scores 6 months .708 (.137) .684 (.149) .759 (.121) .769 (.116) .708 (.130) .724 (.130)
CHU9D utility scores 12 months .875 (.151) .837 (.165) .903 (.138) .875 (.148) .885 (.141) .888 (.143)
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Table 3 Primary outcome results: ITT and per protocol regression analyses baseline—6 months, and effect sizes, of Conners Global Index and Health-Related Quality of Life measure CHU-9D,
according to carers and teachers
Outcome Completer ITT/per
protocol
R2 Hom (n = 29 (ITT), n = 20 (received) NT (n = 28 (ITT), n = 24 received)
Ba (S.E.) t C.I. Effect sizeb B (S.E.) t C.I. Effect sizeb
CGI Carer ITT .215 1.7 (1.57) 1.08, p = .28 − 1.48, 4.81 .425# 2.66 (1.55) 1.71, p = .09 − .347, 5.89 .388
Received .207 1.65 (1.72) .96, p = .34 − 1.84, 5.06 .356 3.05 (1.6) 1.9, p = .062 − .044, 6.44 .55#
Teacher ITT .290 .58 (2.89) .2, p = .84 − 5.37, 6.53 .069 4.11 (3.14) 1.31, p = .2 − 2.35, 10.58 .39
Received .176 .572 (3.16) .18, p = .86 − 6.09, 7.24 .109 − 1.98 (4.15) − .477, p = .64 − 10.74, 6.78 −.504
Restless-
impulsive
Carer ITT .171 .437 (1.19) .368, p = .71 − 1.9, 2.8 .198 2.13 (1.18) 1.8, p = .075 − .22, 4.47 .418#
Received .181 .594 (1.3) .456, p = .65 − 2.0, 3.19 .172 2.59 (1.22) 2.11, p = .038* .15, 5.03 .623#
Teacher ITT .264 .176 (2.39) .074, p = .94 − 4.75, 5.1 .016 3.5 (2.6) 1.35, p = .19 − 1.86, 8.85 .421#
Per protocol .144 .456 (2.74) .166, p = .87 − 5.33, 6.24 .097 − .824 (3.6) − .229, p = .82 − 8.42, 6.78 − .339
Emotional
lability
Carer ITT .230 1.23 (.59) 2.09, p = .04* .06, 2.4 .793# .648 (.58) 1.11, p = .27 − .51, 1.81 .269
Per protocol .213 1.02 (.64) 1.59, p = .12 − .27, 2.3 .679# .612 (.6) 1.01, p = .31 − .59, 1.82 .325
Teacher ITT .251 .403 (.75) .537, p = .6 − 1.14, 1.95 .25 .615 (.82) .754, p = .46 − 1.07, 2.3 .195
Per protocol .209 .117 (.737) .158, p = .88 − 1.44, 1.67 .117 − 1.16 (.968) − 1.19, p = .25 − 3.2, .89 − .93#
CHU 9D Carer ITT .102 .057 (.031) 1.84, p = .069 − .12, .01 .43# .084 (.031) 2.73, p = .008* − .15, − .023 1.1#
Per protocol .122 .05 (.035) 1.42, p = .16 − .12, .02 .3 .094 (.03) 2.84, p = .006* − .16, − .03 1.19#
Total number of observations = 88. Analysis controls for age, gender, and ADHD severity
*Outcome reached two-tailed statistical significance level < .05
#Effect size < .4
aUnstandardised coefficient
bEffect size based on Cohen’s d
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Health-related quality of life
At 6 months, treatment groups’ health-related quality of life
(HRQOL) improved whilst that of those continuing with their
usual care did not. Treatment by a nutritional therapist reached
statistical significance: t = 2.73, p = .008, SMD= 1.1, whilst
treatment by a homoeopath did not: t = 1.84, p = .069, SMD
hom = .43 (Table 3). At 12 months, HRQOL continued to
improve for those in the treatment groups, and there was also
a sharp increase in the HRQOL of those in the control group.
Costs
A total of 240 sessions were attended by participants (124
hom; 124 NT), of which the majority (91 hom; 81 NT) were
during the first 6 months. The mean cost of consultations
(including the cost of homoeopathic medicines, nutritional
supplements, room hire, and postage) for 1 year was
£169.31 (hom) and £553.19 (NT). The increased cost of
nutritional therapy compared with homoeopathy was due
to the cost of nutritional supplements (total cost £16,043
over 1 year).
Feasibility
Table 1 summarises feasibility criteria results. The design was
acceptable, with the trial receiving ethical approval and con-
sidered low risk by University of Sheffield health care re-
search governance procedures. The decision to not seek UK
National Health Service (NHS) ethical approval was chal-
lenged, but the trial sponsor and ethics committee confirmed
that it was not required if NHS premises were not used.
A broadly representative ADHD cohort was recruited: 62%
had co-diagnoses; 62% were taking ADHD medication; 67%
had made at least one visit to the doctor; 60% at least one visit
to hospital; one third were taking sleep medications; 95% of
families had accessed or were accessing a parenting class;
46% of families had visited or were visiting psychologists;
56% of children had a teaching assistant, of whom 22% had
one full time; 7% of families were involved with social
workers; 6% of children had been excluded; and 5% involved
with the police.
Recruitment to the cohort was feasible, with sufficient
numbers speedily recruited. The most successful means was
ADHD support groups. There was minimal uptake from
schools approached. It was not possible to recruit from nation-
ally funded ADHD facilities because NHS ethical approval
was required.
Carer Questionnaire 6-month return rates were initially
very low, despite reminders, but improved after addition of a
£10 voucher incentive although continued to be low in those
who had not accepted the offer of a treatment. Carer-rated
treatment effects were sufficient according to the a priori
specified criteria. Sufficient paired outcomes were available
to inform the sample size calculation for the full trial.
Assuming an effect size of .4 for the primary outcome (CGI
total score) and 80% power for equal sample sizes, the re-
sponses of 100 participants per arm will be required. Forty
percent attrition needs to be allowed for, therefore requiring
recruitment of 166 participants per arm.
A single request, with no reminders, was made for Teacher
Questionnaires. This was unfeasible, since they were poorly
and inconsistently returned. There was little missing data in-
dicating that outcome completion methods were manageable.
Treatment acceptance rates were feasible, but non-take up
of the offer—post-acceptance—was greater than anticipated,
meaning crossover from treatment to usual care was high, and
attrition from consultations therefore also high. Uptake was
affected by therapist’s contacting strategies: most therapists
used a variety of modes and had contacting rates of 60% +;
however, two therapists using a clinic receptionist had
contacting rates of 33% and 25%, and one therapist relying
only on email a contact rate of 33%.
Consultations were conducted at complementary health
clinics, participant’s homes, by telephone, or on-line. They
consisted of an initial consultation of 1½ h and up to seven
follow-up appointments of 30–40 min at 4–6-week intervals.
The initial homoeopathic consultation focused on building
up a complete picture of the participant, asking about medical
history, life events, likes and dislikes, lifestyle, behaviour, and
personality. Prescription of homoeopathic medicines was
made by matching the composite of symptoms and patient
characteristics with those of an appropriate medicine. At
follow-up consultations, carer and child were asked about
changes in symptoms and prescriptions continued with or
changed according to the response.
The initial nutritional therapy consultation asked about diet
preferences, types of food eaten, typical daily diet, food intol-
erances, lifestyle, stressors, family history, diagnoses, health
concerns, and diet-related symptoms. Therapists then provid-
ed participants with a summary sheet with a range of individ-
ually tailored options and meal suggestions. At subsequent
consultations, the plan was reviewed and revised dependent
on the family’s ability to assimilate and put suggestions into
practice. Options included the following: elimination diets
(e.g. gluten free and/or casein free); reducing intake of known
problematic substances (e.g. food colourings, sugars); increas-
ing intake of healthy foods (e.g. oily fish, nuts, seeds, fruit,
vegetables); substituting less healthy foods with healthier
ones; balancing blood sugar; improving drinks/fluids intake;
lifestyle advice (e.g. sleep, activity, purpose, relaxation, time
outdoors); specific dietary interventions for symptoms; and
supplementation (e.g. polyunsaturated fatty acids, multi-vita-
mins, pro-biotics).
Therapists conducting on-line consultations commented
that they liked them, and observed that they may have
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improved attendance. Nutritional therapists offered carers the
choice about whether to attend with their child and most chose
not to. Homoeopaths preferred to see both carer and child.
Sufficient therapists were recruited, but one was not suitable
for this group of patients and dropped out of the study.
Uniquely, her participants registered negative change scores
and a homoeopathic adverse event. All therapists expressed
frustration at the difficulty of making contact, the amount of
last-minute cancellations, and the levels of non-attendance.
Adverse events
The researchers concurred that one moderate Grade 2 event of
worsening behaviour and two mild Grade 1 adverse events of
itchy skin and increased aggression were reactions to nutri-
tional supplements. Onemoderate Grade 2 event of a skin rash
was considered a probable reaction to homoeopathic
treatment.
Discussion
The aim of the Sheffield Treatments for ADHD Research
(STAR) project is to improve outcomes for children with
ADHD by developing a facility for efficiently and objectively
testing the long-term effectiveness of multiple interventions.
This small-scale test suggests that the TwiCs design and pro-
cedures are feasible to achieve this aim with minor adjust-
ments. The interventions trialled were sufficiently effective
and acceptable according to feasibility parameters, and now
require adequately powered testing. Although small effect
sizes were found, these may have been influenced by thera-
pist’s contacting strategies and attrition, and can be addressed.
Most feasibility criteria parameters were met: the primary
outcome was sufficiently sensitive; recruitment procedures
were satisfactory; outcome collection from carers worked well
after the addition of an incentive, although could still be fur-
ther improved, particularly concerning collection of outcomes
from those who chose not to have treatment; the sample of
participants recruited was broadly representative of those with
ADHD; no serious adverse events attributable to treatment
occurred; sufficient therapists were recruited although one
was unsuitable for this population.
The methods used to obtain outcomes from teachers were
not adequate and require improvement. Different and more
approaches are needed to contact schools. Collection is impor-
tant because blinded teacher outcomes provide objective as-
sessments of behaviour in group settings, the majority of early
year costs of ADHD are in education [17] and decisionmakers
prioritise blinded results. There are issues with outcome col-
lection from both carers and teachers. The concern with carer
results is that they are unblinded and carers may be invested in
treatment success which may affect their ratings [25]. The
issue with teacher outcomes is that subtle changes may not
be observed in busy classrooms, children may behave differ-
ently in structured environments, and collection of teacher
outcomes are associated with procurement difficulties, com-
pletion by multiple teachers, and inability to collect outcomes
during school holidays [2].
Both the interventions trialled are complex, comprising
multiple, interacting components; they provide similar time,
attention, and individually tailored advice; something to ingest
between consultations; and are delivered by empathic practi-
tioners. They differ in that implementation of dietary changes
requires more effort than homoeopathic treatment;
homoeopaths prefer attendance of both carer and child at con-
sultations; and nutritional therapy is backed by explanations
of mechanism and trials demonstrating the efficacy of some
supplements and dietary approaches [24], whilst explanations
of a mechanism for the action of homoeopathic medicines is
not established, although four trials suggest the efficacy of
individually tailored homoeopathic medicines [1, 9, 15, 19].
As befits a pragmatic trial, both interventions were trialled as
experienced in clinical practice, and results reflect the effects
of being offered this experience, not the efficacy of the
ingested substances (homoeopathic medicines, nutritional
supplements, or dietary inclusions/exclusions).
Implications for future research
Some carers reported to their therapists that implementation of
nutritional advice improved the nutrition of the whole family;
and that implementation of homoeopathic treatment improved
unexpected aspects such as gut dysbiosis, anxiety, eczema,
and medication side effects. A future study might assess these
anecdotal observations more systematically.
The TwiCs approach to conducting pragmatic trials can ad-
dress important gaps in ADHD research, facilitate fast and ef-
ficient recruitment of participants, and provide useful informa-
tion to stakeholders. Successful recruitment to the STAR cohort
is likely to have been accomplished due to minimal commit-
ment or delusion regarding interventions. However, the TwiCs
approach uses a two-stage approach to informed consent, and
participants, whilst easily recruited to the cohort (the first stage),
were less easily retained at the second stage (the trial).
Greater refusal of the offer is to be expected using the
TwiCs design compared with traditional RCT designs, where
those not happy to accept a treatment or a placebo refuse
participation prior to randomisation [33]. Whilst traditional
RCTs often struggle to recruit sufficient participants (numbers
declining are generally not recorded), they may better retain
those they do recruit. However, information about acceptabil-
ity is a useful feature of the TwiCs design, providing important
information to stakeholders because: mainstream treatments
for ADHD are not particularly acceptable and attrition and
non-take up are a feature [16, 22]; information across trials
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with similar degrees of pragmatism can be useful; there is little
point in having efficacious or effective interventions if they
are not acceptable to their population; and uncertainty still
remains regarding the effectiveness of the two mainstream
intervention types (pharmaceutical medication and behaviour-
al change programmes) in routine clinical practice.
The evidence base for child and adolescent mental health
interventions to improve long-term mental health, is minimal
[8, 14]. Reasons given are that relevant interventions are gener-
ally complex and multi-dimensional [13]; levels of comorbidity
are high; and research expensive, labour intensive, and requiring
specially trained staff [18]. The comparative effectiveness of
mainstream interventions for ADHD is difficult to ascertain due
to the use of different trial designs and samples [20, 28, 29], and
their long-term effectiveness is also unknown. The TwiCs ap-
proach provides a potential solution to these issues. It is already
being successfully implemented in five cohorts of children sim-
ilar to the STAR ADHD cohort in being at risk of long-term
negative outcomes (https://www.twics.global/use-of-the-
design). Taking innovative pre-emptive approaches by develop-
ing cohorts and testing multiple interventions to try and improve
outcomes is an emerging strength and potential of the design.
The STAR cohort now requires expanding, focusing on
recruitment of those most at need: teenagers, hard to reach
families, those with co-occurring autism, looked after chil-
dren, those involved in criminality, and those with multiple
co-morbidities. Improvement in collection of teacher out-
comes and therapist’s contacting strategies are needed, by im-
proving links with schools, increasing the number of re-
minders to teachers, and using multiple contacting modes to
both carers and teachers.
The two piloted interventions now require testing in greater
numbers. Future studies will need to address stakeholder con-
cerns regarding the generalisability and variability of
therapist-led interventions. However, both interventions ap-
pear safe, potentially effective, cheap to implement, and may
be particularly useful: in the early years before pharmaceutical
medication is permitted; for the 25%+ children with ADHD
who cannot tolerate pharmaceutical medications; and for teen-
agers opting to discontinue their pharmaceutical medications.
Further trials of other main and non-mainstream interventions
are also planned.
Conclusion
Children with ADHD are at risk of negative outcomes and in
need of pre-emptive strategies implemented as early as possi-
ble. The STAR project demonstrated the feasibility and utility
of the TwiCs approach to pragmatic RCT design for children
with ADHD. It can make a useful contribution in the search to
improve outcomes for those with ADHD.
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